Murae Organisor Ltd
Incorporated in 2012, Murae Organisor Ltd
is in the business of pharma commodities
trading[1]
- Market Cap ₹ 149 Cr.
- Current Price ₹ 0.73
- High / Low ₹ 1.24 / 0.48
- Stock P/E 9.82
- Book Value ₹ 1.02
- Dividend Yield 0.00 %
- ROCE 4.21 %
- ROE 5.69 %
- Face Value ₹ 1.00
Pros
- Stock is trading at 0.72 times its book value
- Company has delivered good profit growth of 32.8% CAGR over last 5 years
- Debtor days have improved from 623 to 108 days.
Cons
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 5.10% over last 3 years.
- Company might be capitalizing the interest cost
- Earnings include an other income of Rs.9.00 Cr.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | 9 | 19 | 23 | 35 | 51 | 55 | 41 | 21 | 14 | 3 | 855 | 859 | |
0 | 9 | 18 | 23 | 34 | 47 | 54 | 49 | 25 | 13 | 4 | 845 | 847 | |
Operating Profit | 0 | 0 | 1 | 0 | 2 | 3 | 1 | -8 | -4 | 1 | -1 | 10 | 11 |
OPM % | 2% | 3% | 2% | 4% | 7% | 2% | -19% | -21% | 7% | -44% | 1% | 1% | |
0 | 0 | 0 | 0 | 0 | 0 | 2 | 9 | 8 | 2 | 2 | 0 | 9 | |
Interest | 0 | 0 | 0 | 1 | 1 | 1 | 1 | 1 | 0 | 0 | 0 | 0 | 0 |
Depreciation | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Profit before tax | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 3 | 3 | 0 | 10 | 20 |
Tax % | 31% | 44% | 33% | 27% | 27% | 26% | 25% | 28% | 29% | 29% | 25% | ||
0 | 0 | 0 | 0 | 1 | 2 | 2 | 0 | 2 | 2 | 0 | 8 | 15 | |
EPS in Rs | 0.07 | 0.11 | 0.23 | 0.42 | 0.02 | 0.00 | 0.02 | 0.02 | 0.00 | 0.04 | 0.07 | ||
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 58% |
5 Years: | 73% |
3 Years: | 244% |
TTM: | 44618% |
Compounded Profit Growth | |
---|---|
10 Years: | 53% |
5 Years: | 33% |
3 Years: | 50% |
TTM: | 15100% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | -23% |
3 Years: | -10% |
1 Year: | 16% |
Return on Equity | |
---|---|
10 Years: | 7% |
5 Years: | 5% |
3 Years: | 5% |
Last Year: | 6% |
Balance Sheet
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 0.01 | 0.01 | 0.11 | 0.11 | 0.31 | 0.31 | 6 | 6 | 12 | 12 | 49 | 186 |
Reserves | 0 | 1 | 1 | 1 | 5 | 6 | 8 | 8 | 4 | 6 | 6 | 23 |
0 | 1 | 2 | 2 | 7 | 10 | 9 | 11 | 9 | 9 | 0 | 213 | |
0 | 3 | 6 | 7 | 7 | 8 | 12 | 2 | 3 | 1 | 64 | 231 | |
Total Liabilities | 0 | 5 | 9 | 11 | 20 | 23 | 36 | 28 | 29 | 29 | 120 | 652 |
0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 | 0 | 0 | 0 | |
CWIP | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 3 | 0 | 0 | 0 | 0 | 0 |
0 | 5 | 9 | 11 | 19 | 23 | 32 | 27 | 28 | 28 | 120 | 652 | |
Total Assets | 0 | 5 | 9 | 11 | 20 | 23 | 36 | 28 | 29 | 29 | 120 | 652 |
Cash Flows
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
0 | -2 | -0 | 0 | -7 | -0 | -3 | -7 | 3 | 0 | -16 | -323 | |
0 | -0 | -0 | -0 | -0 | -0 | -3 | 3 | 0 | 0 | -0 | -0 | |
0 | 2 | 1 | -0 | 7 | 1 | 7 | 3 | -3 | -0 | 28 | 358 | |
Net Cash Flow | 0 | 0 | 0 | -0 | -0 | 0 | -0 | -1 | -0 | -0 | 12 | 35 |
Ratios
Figures in Rs. Crores
Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 125 | 87 | 56 | 111 | 78 | 112 | 95 | 261 | 217 | 1,543 | 108 | |
Inventory Days | 71 | 78 | 108 | 91 | 86 | 97 | 122 | 179 | 392 | 1,439 | 1 | |
Days Payable | 113 | 107 | 83 | 77 | 54 | 83 | 10 | 18 | -25 | 7 | 85 | |
Cash Conversion Cycle | 82 | 58 | 82 | 125 | 111 | 126 | 207 | 422 | 635 | 2,975 | 24 | |
Working Capital Days | 81 | 24 | 34 | 64 | 57 | 79 | 143 | 279 | 472 | 6,342 | 160 | |
ROCE % | 0% | 22% | 21% | 22% | 25% | 24% | 17% | 4% | 12% | 12% | 1% | 4% |
Documents
Announcements
-
Intimation Under Regulation 30 Of SEBI (LODR), 2015 - Strategic Evaluation Of Agro R&D And Infrastructure Initiatives (Post QIP)
28 Aug - QIP up to ₹80 Cr proposed to fund agro R&D, processing, working capital.
- Announcement under Regulation 30 (LODR)-Newspaper Publication 23 Aug
-
Announcement under Regulation 30 (LODR)-Press Release / Media Release
22 Aug - Accumulated Rs.297 crore supply orders; FY25 revenue Rs.854.82cr; net profit Rs.7.52cr; 1:2 stock split; bonus/dividend proposed
-
Submission Of Integrated Financial Results For The Quarter Ended On 30Th June, 2025
22 Aug - Q1 30-Jun-2025 results: profit Rs743.56 lacs; auditor issued disclaimer citing missing documents.
- Submission Of Results For The Quarter Ended On 30Th June 2025 22 Aug
Business Overview:[1][2][3]
a) MOL is in the business of manufacturing Pharmaceutical, Nutraceutical, Ayurvedic
Herbal products, and trading of pharma
products.
b) It acts as a commission agent in pharma products etc.
c) It provides premium cattle feed which is formulated to support livestock health and performance, while its fertilizers and chemicals are designed to optimize crop yields and ensure safety.
d) It also offers expertise in the gold sector, providing insights and services related to this precious metal